Anticyclic citrullinated peptide antibody in rheumatoid arthritis:a cross-sectional study in Iran | Zendy

Irandokht Shenavar Masooleh | Zendy; Asghar Hajiabbasi | Zendy; Habib Zayeni | Zendy; Atefeh Ghanbari | Zendy; Violet Zaker Esteghamati | Zendy; Banafsheh GhavidelParsa | Zendy; Amir Hassankhani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anticyclic citrullinated peptide antibody in rheumatoid arthritis:a cross-sectional study in Iran

Author(s) -

Irandokht Shenavar Masooleh,

Asghar Hajiabbasi,

Habib Zayeni,

Atefeh Ghanbari,

Violet Zaker Esteghamati,

Banafsheh GhavidelParsa,

Amir Hassankhani

Publication year - 2016

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-1502-27

Subject(s) - medicine , rheumatoid arthritis , rheumatoid factor , erythrocyte sedimentation rate , titer , antibody , antibody titer , joint disease , gastroenterology , immunology , pathology , osteoarthritis , alternative medicine

Studies have shown that anticyclic citrullinated peptide antibody (anti-CCP) titers can be useful in the diagnosis of rheumatoid arthritis (RA). We evaluate the association between anti-CCP antibody titers and the demographic, clinical, and laboratory characteristics of RA patients. Moreover, we explore whether there is any relation between joint destruction and demographic and clinical characteristics of RA patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research